Log In Get Started
Press Releases April 30, 2026 11:23 AM

Voting Rights and Capital

Shell plc reports updated total voting rights and share capital figures as of April 30, 2026

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
SHEL

Shell plc announced that as of April 30, 2026, its capital consists of 5,607,066,071 ordinary shares with no shares held in treasury. This update serves as a reference figure for shareholders to assess voting rights and disclosure requirements under the FCA's Transparency Rules. The figure includes shares involved in the ongoing share buy-back program but not yet cancelled.

Voting Rights and Capital
SHEL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Shell plc's total issued ordinary shares amount to 5,607,066,071 as of April 30, 2026.
  • No shares are held in treasury by Shell plc at this time.
  • The figure includes shares purchased via the share buy-back program but not yet cancelled, important for shareholder notifications under FCA rules.

Total Voting Rights

In conformity with the Disclosure Guidance and Transparency Rules, we hereby notify the market of the following:

Shell plc's capital as at April 30, 2026, consists of 5,607,066,071 ordinary shares of €0.07 each. Shell plc holds no shares in Treasury.

The figure, 5,607,066,071, may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Shell plc under the FCA's Disclosure Guidance and Transparency Rules.

Note: This announcement is made pursuant to Disclosure Guidance and Transparency Rule 5.6.1 and as such, the above figure includes shares purchased by Shell plc as part of its share buy-back programme but not yet cancelled.

Enquiries


Shell Media Relations
International +44 (0)207 934 5550; U.S. and Canada: Contact form


Risks

  • The share buy-back program shares are accounted for in total voting rights but remain subject to cancellation, causing possible future adjustments in shares outstanding.
  • Regulatory compliance requires precise disclosure of shareholdings, so any changes in the share structure could impact shareholder notifications and market perception.
  • Market fluctuations or unforeseen corporate actions could affect the share capital and voting rights beyond the reported figure.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026